EP1994940 - Therapeutic use of erythropoietin omega [Right-click to bookmark this link] | |||
Former [2008/48] | THERAPEUTIC USE OF A RECOMBINANT ERYTHROPOIETIN HAVING HIGH ACTIVITY AND REDUCED SIDE EFFECTS | ||
[2011/40] | Status | No opposition filed within time limit Status updated on 08.03.2013 Database last updated on 24.08.2024 | Most recent event Tooltip | 30.05.2014 | Lapse of the patent in a contracting state New state(s): LU | published on 02.07.2014 [2014/27] | Applicant(s) | For all designated states Baxter Healthcare S.A. Thurgauerstrasse 130 8152 Glattpark (Opfikon) / CH | [2010/01] |
Former [2008/48] | For all designated states Baxter Healthcare SA Hertistrasse 2 8304 Wallisellen / CH | Inventor(s) | 01 /
Thompson, Lawrence H. EP Griffin Companies 704 228th Avenue NE Suite 791 Sammamish Washington 98101 / US | [2012/18] |
Former [2008/48] | 01 /
Thompson, Lawrence H. EP Griffin Companies 704 228th Avenue NE Suite 791 Sammamish Washington 98101 / US | Representative(s) | Bassett, Richard Simon, et al Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB | [N/P] |
Former [2008/48] | Bassett, Richard Simon, et al Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham NG1 5DD / GB | Application number, filing date | 07075711.7 | 09.08.2001 | [2008/48] | Priority number, date | US20000637962 | 11.08.2000 Original published format: US 637962 | [2008/48] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP1994940 | Date: | 26.11.2008 | Language: | EN | [2008/48] | Type: | B1 Patent specification | No.: | EP1994940 | Date: | 02.05.2012 | Language: | EN | [2012/18] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 08.10.2008 | Classification | IPC: | A61K38/18, A61P25/00, A61P9/00 | [2008/48] | CPC: |
A61K38/1816 (EP,US);
A61K38/22 (KR);
A61P1/18 (EP);
A61P13/12 (EP);
A61P25/00 (EP);
A61P25/28 (EP);
A61P29/00 (EP);
A61P35/00 (EP);
A61P37/06 (EP);
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2008/48] | Extension states | AL | 06.09.2007 | LT | 06.09.2007 | LV | 06.09.2007 | MK | 06.09.2007 | RO | 06.09.2007 | Title | German: | Therapeutische Verwendung von Erythropoietin omega | [2011/40] | English: | Therapeutic use of erythropoietin omega | [2011/43] | French: | Utilisation thérapeutique d'érythropoïétine omega | [2011/40] |
Former [2008/48] | Therapeutische Verwendung von rekombinanten Erythropoietin mit hoher Wirksamkeit und geringen Nebenwirkungen | ||
Former [2008/48] | THERAPEUTIC USE OF A RECOMBINANT ERYTHROPOIETIN HAVING HIGH ACTIVITY AND REDUCED SIDE EFFECTS | ||
Former [2008/48] | Utilisation thérapeutique d'érythropoïétine recombinante dotée d'un forte activité et d'effets secondaires réduits | Examination procedure | 06.09.2007 | Examination requested [2008/48] | 11.12.2007 | Loss of particular rights, legal effect: Claims | 23.01.2008 | Despatch of communication of loss of particular rights: Claims {1} | 11.02.2009 | Amendment by applicant (claims and/or description) | 11.12.2009 | Despatch of a communication from the examining division (Time limit: M06) | 02.06.2010 | Reply to a communication from the examining division | 08.06.2011 | Despatch of a communication from the examining division (Time limit: M02) | 14.07.2011 | Reply to a communication from the examining division | 29.09.2011 | Communication of intention to grant the patent | 03.02.2012 | Fee for grant paid | 03.02.2012 | Fee for publishing/printing paid | Parent application(s) Tooltip | EP01971896.4 / EP1317276 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20010971896) is 09.06.2005 | Opposition(s) | 05.02.2013 | No opposition filed within time limit [2013/15] | Fees paid | Renewal fee | 06.09.2007 | Renewal fee patent year 03 | 06.09.2007 | Renewal fee patent year 04 | 06.09.2007 | Renewal fee patent year 05 | 06.09.2007 | Renewal fee patent year 06 | 06.09.2007 | Renewal fee patent year 07 | 25.08.2008 | Renewal fee patent year 08 | 25.08.2009 | Renewal fee patent year 09 | 25.08.2010 | Renewal fee patent year 10 | 25.08.2011 | Renewal fee patent year 11 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AT | 02.05.2012 | BE | 02.05.2012 | CY | 02.05.2012 | DK | 02.05.2012 | FI | 02.05.2012 | IT | 02.05.2012 | NL | 02.05.2012 | SE | 02.05.2012 | TR | 02.05.2012 | GR | 03.08.2012 | IE | 09.08.2012 | LU | 09.08.2012 | ES | 13.08.2012 | CH | 31.08.2012 | LI | 31.08.2012 | MC | 31.08.2012 | PT | 03.09.2012 | [2014/27] |
Former [2014/21] | AT | 02.05.2012 | |
BE | 02.05.2012 | ||
CY | 02.05.2012 | ||
DK | 02.05.2012 | ||
FI | 02.05.2012 | ||
IT | 02.05.2012 | ||
NL | 02.05.2012 | ||
SE | 02.05.2012 | ||
TR | 02.05.2012 | ||
GR | 03.08.2012 | ||
IE | 09.08.2012 | ||
ES | 13.08.2012 | ||
CH | 31.08.2012 | ||
LI | 31.08.2012 | ||
MC | 31.08.2012 | ||
PT | 03.09.2012 | ||
Former [2013/33] | AT | 02.05.2012 | |
BE | 02.05.2012 | ||
CY | 02.05.2012 | ||
DK | 02.05.2012 | ||
FI | 02.05.2012 | ||
IT | 02.05.2012 | ||
NL | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
IE | 09.08.2012 | ||
ES | 13.08.2012 | ||
CH | 31.08.2012 | ||
LI | 31.08.2012 | ||
MC | 31.08.2012 | ||
PT | 03.09.2012 | ||
Former [2013/22] | AT | 02.05.2012 | |
BE | 02.05.2012 | ||
CY | 02.05.2012 | ||
DK | 02.05.2012 | ||
FI | 02.05.2012 | ||
IT | 02.05.2012 | ||
NL | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
ES | 13.08.2012 | ||
CH | 31.08.2012 | ||
LI | 31.08.2012 | ||
MC | 31.08.2012 | ||
PT | 03.09.2012 | ||
Former [2013/20] | AT | 02.05.2012 | |
BE | 02.05.2012 | ||
CY | 02.05.2012 | ||
DK | 02.05.2012 | ||
FI | 02.05.2012 | ||
IT | 02.05.2012 | ||
NL | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
CH | 31.08.2012 | ||
LI | 31.08.2012 | ||
MC | 31.08.2012 | ||
PT | 03.09.2012 | ||
Former [2013/16] | AT | 02.05.2012 | |
BE | 02.05.2012 | ||
CY | 02.05.2012 | ||
DK | 02.05.2012 | ||
FI | 02.05.2012 | ||
IT | 02.05.2012 | ||
NL | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
MC | 31.08.2012 | ||
PT | 03.09.2012 | ||
Former [2013/11] | AT | 02.05.2012 | |
BE | 02.05.2012 | ||
CY | 02.05.2012 | ||
DK | 02.05.2012 | ||
FI | 02.05.2012 | ||
IT | 02.05.2012 | ||
NL | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
PT | 03.09.2012 | ||
Former [2013/08] | AT | 02.05.2012 | |
BE | 02.05.2012 | ||
CY | 02.05.2012 | ||
DK | 02.05.2012 | ||
FI | 02.05.2012 | ||
NL | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
PT | 03.09.2012 | ||
Former [2013/07] | AT | 02.05.2012 | |
BE | 02.05.2012 | ||
CY | 02.05.2012 | ||
FI | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
PT | 03.09.2012 | ||
Former [2013/04] | BE | 02.05.2012 | |
CY | 02.05.2012 | ||
FI | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
PT | 03.09.2012 | ||
Former [2013/01] | CY | 02.05.2012 | |
FI | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
PT | 03.09.2012 | ||
Former [2012/50] | CY | 02.05.2012 | |
FI | 02.05.2012 | ||
SE | 02.05.2012 | ||
GR | 03.08.2012 | ||
Former [2012/49] | CY | 02.05.2012 | |
FI | 02.05.2012 | ||
SE | 02.05.2012 | ||
Former [2012/48] | FI | 02.05.2012 | |
SE | 02.05.2012 | Documents cited: | Search | [A]WO8800241 (UNIV WASHINGTON [US]) [A] 1-10 * page 2, line 6 - line 14; claim - *; | [A]WO0024893 (AMGEN INC [US]) [A] 1-10 * page 4, line 30 - page 7, line 10; claim - *; | [Y] - H. LUDWIG, "Epoetin in cancer-related anaemia", NEPHROLOGY DIALYSIS TRANSPLANTATION, (199902), vol. 14, no. suppl 2, pages 85 - 92, XP002219608 [Y] 1-10 * the whole document * DOI: http://dx.doi.org/10.1093/ndt/14.suppl_2.85 | [Y] - CAN ERYTHROPOIETIN STUDYGROUP, "ASSOCIATION BETWEEN RECOMBINANT HUMAN ERYTHROPOIETIN AND QUALITY OF LIFE AND EXERCISE CAPACITY OF PATIENTS RECEIVING HEMODIALYSIS", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (1990), Database accession no. PREV199089118498, XP002219609 [Y] 1-10 * abstract * | [PA] - S. MILUTINOVIC ET AL., "Erythropoietin-induced hypertension in dialyzed uremics is influenced by glycosylation patterns of the molecule.", NEPHROLOGY DIALYIS TRANSPLANTATION, (200106), vol. 16, no. 6, page A91, XP008010133 [PA] 1-10 * abstract * DOI: http://dx.doi.org/10.1093/ndt/16.1.1 | [PA] - S. MILUTINOVIC ET AL., "Differences in glycosylation structures have an important impact on potency and pharmacokinetics of erythropoietin (EPO) in dialyzed uremics.", NEPHROLOGY DIALYSIS TRANSPLANTATION, (200009), vol. 15, no. 9, page A156, XP008010132 [PA] 1-10 * abstract * | [ ] - BRITISH MEDICAL JOURNAL, (1990), vol. 300, no. 6724, ISSN 0959-8138, pages 573 - 578 |